Journal
DIABETES & METABOLISM
Volume 30, Issue 5, Pages 459-463Publisher
MASSON EDITEUR
DOI: 10.1016/S1262-3636(07)70143-X
Keywords
CD36; type 2 diabetes; insulin-resistance; adiponectin; genetics
Categories
Funding
- Medical Research Council [G0000477, MC_U120061454] Funding Source: Medline
- Medical Research Council [MC_U120061454, G0000477] Funding Source: researchfish
- MRC [G0000477, MC_U120061454] Funding Source: UKRI
Ask authors/readers for more resources
Objectives: CD36 is a multifunctional membrane receptor widely expressed in different tissues which binds and internalizes oxidized low-density lipoprotein. In rodents, CD36 gene variations modulate glucose homeostasis and contribute to metabolic syndrome associated with type 2 diabetes but the effects in human are unknown. Methods: We screened the entire coding sequence of the CD36 gene in 272 individuals and we genotyped both rare and frequent variants in 454 T2D subjects and 221 controls. Results: We detected five mutations, P191P and N247S were only found each in one family and did not segregate with diabetes, the three others (A/C-178 in the promoter, A/G-10 in intron 3 and (GGGTTGAGA) insertion in intron 13) being equally frequent in diabetic subjects and in controls. However, adiponectin levels; a marker for insulin sensitivity, were significantly associated with the -178 A/C promoter variant allele (p = 0.003, p corrected for multiple testing = 0.036), possibly reflecting association with insulin-resistance in the French population. Conclusion: Thus, the -178 A/C SNP promoter mutation in the CD36 gene represents a putative genetic marker for insulin-resistance in the French population, although it does not appear to contribute to the genetic risk for T2D.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available